Leadership Expansion Recent executive hiring of Dr. Aidan Synnott as CEO signals a strategic shift and potential bolstering of business development, partnerships, and client engagement efforts to accelerate drug discovery collaborations.

M&A and Partnerships Acquisition of ZoBio BV and active partnerships with ImaginAb Inc. and Veritas In Silico indicate a growth and diversification strategy that expands capabilities and market reach, presenting upsell and cross-sell opportunities in radiopharmaceuticals, imaging, and in silico drug discovery services.

Therapeutic Focus Specialization in targeted radiotherapy, oncology, immuno-oncology, and inflammatory diseases aligns with high-value preclinical needs from biopharma firms pursuing IND-enabling studies, enabling tailored trial workups and evidence-generation packages.

Geographic and Market Growth European-led CRO with growing capabilities through acquisitions and collaborations presents a compelling entry point for regional biotech and pharma clients seeking preclinical services with translational imaging and mechanism of action studies.

Scale and Capabilities AAALAC accreditation, multi-decade imaging and translational pharmacology experience, and a 51-200 employee base position Oncodesign Services as a scalable partner for mid-sized pharma companies requiring robust, compliant preclinical programs and long-term collaboration.